
PALVELLA THERAPEUTICS, INC.
Nasdaq · Pharmaceutical Preparations
Company Overview
A concise company profile alongside the latest public filing activity.
Palvella Therapeutics is a clinical-stage biopharmaceutical company developing treatments for rare, serious skin diseases, including its lead candidate QTORIN 3.9% anhydrous gel, a topical rapamycin formulation being studied for conditions such as microcystic lymphatic malformations and pachyonychia congenita.
Company profile sourced from SEC filings.
Corporate Insider Trades
Open-market purchases and sales by directors, officers, and other company insiders.
| Insider | Type | Value | Shares / Price | Date |
|---|---|---|---|---|
| JENKINS GEORGE MDirector | Sell | $676K | 5,095at $132.62 | Oct 12, 2026 |
| JENKINS GEORGE MDirector | Sell | $448K | 3,335at $134.21 | Oct 12, 2026 |
| JENKINS GEORGE MDirector | Sell | $328K | 2,458at $133.25 | Oct 12, 2026 |
| JENKINS GEORGE MDirector | Sell | $321K | 2,604at $123.29 | Oct 14, 2026 |
| JENKINS GEORGE MDirector | Sell | $258K | 2,004at $128.52 | Oct 13, 2026 |
| JENKINS GEORGE MDirector | Sell | $254K | 2,072at $122.62 | Oct 14, 2026 |
| JENKINS GEORGE MDirector | Sell | $212K | 1,644at $129.23 | Oct 13, 2026 |
| JENKINS GEORGE MDirector | Sell | $196K | 1,447at $135.50 | Oct 12, 2026 |
| JENKINS GEORGE MDirector | Sell | $136K | 1,035at $131.49 | Oct 13, 2026 |
| JENKINS GEORGE MDirector | Sell | $129K | 990at $130.48 | Oct 13, 2026 |
| JENKINS GEORGE MDirector | Sell | $123K | 922at $133.72 | Oct 13, 2026 |
| JENKINS GEORGE MDirector | Sell | $114K | 920at $124.37 | Oct 14, 2026 |
| JENKINS GEORGE MDirector | Sell | $111K | 817at $136.44 | Oct 12, 2026 |
| JENKINS GEORGE MDirector | Sell | $77K | 579at $132.40 | Oct 13, 2026 |
| JENKINS GEORGE MDirector | Sell | $75K | 597at $125.33 | Oct 14, 2026 |
| JENKINS GEORGE MDirector | Sell | $64K | 505at $126.55 | Oct 14, 2026 |
| JENKINS GEORGE MDirector | Sell | $58K | 476at $121.14 | Oct 14, 2026 |
Source: SEC EDGAR Form 4 filings
Congressional Trades
Recent disclosures by members of the U.S. House and Senate.
Source: Senate eFD and House Clerk STOCK Act disclosures
Get notable PVLA activity by email
Free alerts for the insider and congressional trades worth watching.
For informational purposes only, not investment advice. Filings can be delayed, corrected, or amended. Trading activity alone does not predict future performance.